Catalyst Dossier · compiled by CeliA 🧫

Allergy Therapeutics plc (AGY.L)

Pharmaceutical Preparations · market cap $6M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
sublingual immunotherapy	Phase 2	Seasonal Rhinitis and/or Rhinoconjunctivitis
PURETHAL Mites 50,000 AUeq/ml	Phase 3	House Dust Mite Allergy
SUBLIVAC FIX phleum prat.	Phase 2	Allergic Rhinitis
Grass MATAMPL	Phase 2	Type I Hypersensitivity
Tree MATA MPL	Phase 2	Type I Hypersensitivity
PURETHAL Mites 6,667 AU/ml	Phase 2	Allergic Rhinitis
Grass MATA MPL (0.5ml) 5100SU	Phase 2	Seasonal Allergic Rhinitis
TreeMATA MPL	Phase 2	Type I Hypersensitivity
Ragweed MATA MPL	Phase 3	Type I Hypersensitivity
PQ Grass	Phase 3	Rhinitis, Allergic, Seasonal
SUBLIVAC FIX Mite mixture	Phase 2	House Dust Mite Allergy
Ragweed MATAMPL	Phase 2	Type I Hypersensitivity
Tree MATA MPL - Therapeutic Regimen	Phase 2	Type I Hypersensitivity
RagweedMATAMPL	Phase 2	Type I Hypersensitivity
Grass MATA MPL	Phase 3	Type I Hypersensitivity

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AGY.L (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 15 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.